Aylin Altan Riedel1, Mike Nelson, Katrine Wallace, Nancy Joseph-Ridge, Michele Cleary, Adel G Fam. 1. From *Ingenix Inc., Eden Prairie, Minnesota; †TAP Pharmaceutical Products Inc., Lake Forest, Illinois; the ‡University of Illinois at Chicago School of Public Health, Chicago, Illinois; and §Sunnybrook and Womenʼs College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: : Comorbid disorders and multiple prescription drug use are common among patients with gout and/or hyperuricemia and may influence the clinical course and outcome of gout. OBJECTIVE: : We wanted to document the conditions and associated medications in a large group of patients with gout in a managed care setting. METHODS: : This study was a 2-year, retrospective, administrative claims analysis examining comorbid conditions and medication use among managed care enrollees with gout/hyperuricemia across the United States. RESULTS: : Of the 9482 study subjects (82.1% men, mean age 52 years), 57.9% had hypertension, 45.3% had a lipid disorder, 32.5% had both conditions, and 19.9% had diabetes mellitus. During the 24-month follow-up period, subjects had 5 +/- 3.14 (mean +/- standard deviation) different comorbid conditions and filled prescriptions for of 11.0 +/- 7.90 different medications. The most commonly filled prescriptions included antihypertensive drugs, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), and nonsteroidal antiinflammatory drugs (NSAIDs). CONCLUSIONS: : The study indicates a high prevalence of both comorbid conditions and multiple medication use among managed care enrollees with gout and/or hyperuricemia. Heightened awareness of these associated disorders is important because they may warrant treatment of their own accord and often some modification of gout management. Drugs, particularly diuretics and prophylactic aspirin, could potentially contribute to the development of hyperuricemia and gout.
BACKGROUND: : Comorbid disorders and multiple prescription drug use are common among patients with gout and/or hyperuricemia and may influence the clinical course and outcome of gout. OBJECTIVE: : We wanted to document the conditions and associated medications in a large group of patients with gout in a managed care setting. METHODS: : This study was a 2-year, retrospective, administrative claims analysis examining comorbid conditions and medication use among managed care enrollees with gout/hyperuricemia across the United States. RESULTS: : Of the 9482 study subjects (82.1% men, mean age 52 years), 57.9% had hypertension, 45.3% had a lipid disorder, 32.5% had both conditions, and 19.9% had diabetes mellitus. During the 24-month follow-up period, subjects had 5 +/- 3.14 (mean +/- standard deviation) different comorbid conditions and filled prescriptions for of 11.0 +/- 7.90 different medications. The most commonly filled prescriptions included antihypertensive drugs, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins), and nonsteroidal antiinflammatory drugs (NSAIDs). CONCLUSIONS: : The study indicates a high prevalence of both comorbid conditions and multiple medication use among managed care enrollees with gout and/or hyperuricemia. Heightened awareness of these associated disorders is important because they may warrant treatment of their own accord and often some modification of gout management. Drugs, particularly diuretics and prophylactic aspirin, could potentially contribute to the development of hyperuricemia and gout.
Authors: Sophie L Stocker; Andrew J McLachlan; Radojka M Savic; Carl M Kirkpatrick; Garry G Graham; Kenneth M Williams; Richard O Day Journal: Br J Clin Pharmacol Date: 2012-09 Impact factor: 4.335
Authors: U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun Journal: Z Rheumatol Date: 2016-08 Impact factor: 1.372
Authors: Naomi Schlesinger; Marc De Meulemeester; Andrey Pikhlak; A Eftal Yücel; Dominik Richard; Valda Murphy; Udayasankar Arulmani; Peter Sallstig; Alexander So Journal: Arthritis Res Ther Date: 2011-03-25 Impact factor: 5.156